Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Current Deferred Revenue (2016 - 2024)

Seres Therapeutics' Current Deferred Revenue history spans 9 years, with the latest figure at $7.9 million for Q2 2024.

  • For Q2 2024, Current Deferred Revenue rose 181.22% year-over-year to $7.9 million; the TTM value through Jun 2024 reached $7.9 million, up 181.22%, while the annual FY2023 figure was $7.7 million, 81.5% up from the prior year.
  • Current Deferred Revenue for Q2 2024 was $7.9 million at Seres Therapeutics, down from $8.1 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $22.6 million in Q4 2020 and bottomed at $364000.0 in Q3 2023.
  • The 5-year median for Current Deferred Revenue is $8.5 million (2020), against an average of $11.0 million.
  • The largest annual shift saw Current Deferred Revenue tumbled 92.52% in 2023 before it skyrocketed 241.29% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $22.6 million in 2020, then decreased by 25.59% to $16.8 million in 2021, then tumbled by 74.68% to $4.3 million in 2022, then surged by 81.5% to $7.7 million in 2023, then increased by 2.48% to $7.9 million in 2024.
  • Per Business Quant, the three most recent readings for MCRB's Current Deferred Revenue are $7.9 million (Q2 2024), $8.1 million (Q1 2024), and $7.7 million (Q4 2023).